Massachusetts
Prescription drug spending and prescribing in Massachusetts, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $7.6B for prescriptions written in Massachusetts, the 12th most of 52 states and territories, and 2.7% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $7.6B
- Medicaid drugs, 2025: $2.6B
- Opioid share of claims: 2.7%
- Life-science raises, 2 years: $5.5B
How It Prescribes
Medicare Part D, 2024, by the prescriber's state| Share of Part D claims | Massachusetts | United States | Difference |
|---|---|---|---|
| Opioids | 2.7% | 3.5% | -23% |
| Antibiotics | 4.0% | 4.4% | -10% |
| Antipsychotics | 2.4% | 1.7% | +35% |
Most Distinctive Drugs
Prescribed most out of line with the rest of the country: the drug's share of Massachusetts's claims against its share nationally| Drug | Against national rate | Claims |
|---|---|---|
| Cefpodoxime Proxetil | 4.9× | 58,263 |
| Betamethasone/Propylene Glyc | 2.9× | 23,970 |
| Buprenorphine Hcl/Naloxone Hcl | 2.8× | 115,435 |
| Fluticasone Furoate | 2.7× | 39,489 |
| Umeclidinium Bromide | 2.5× | 47,637 |
| Clozapine | 2.4× | 63,970 |
| Methylphenidate Hcl | 2.4× | 48,574 |
| Dextroamphetamine/Amphetamine | 2.3× | 129,865 |
| Lorazepam | 2.3× | 421,339 |
| Beclomethasone Dipropionate | 2.2× | 11,401 |
Biggest Medicaid Drugs
What Massachusetts's Medicaid program paid pharmacies, before rebates; see every drugLife-Science Fundraising
302 Form D raises by companies based in Massachusetts in the last two years; the 10 largest. See all raises- Zai Lab Ltd$250M · Biotech · Nov 9, 2026
- AdvanCell, Inc.$218M · Biotech · Jul 16, 2026
- Odyssey Therapeutics, Inc.$214M · Biotech · Dec 4, 2025
- Treeline Biosciences, Inc.$200M · Biotech · Sep 4, 2025
- LUMICELL, INC.$198M · Biotech · May 6, 2025
- Cognito Therapeutics Group, Inc.$196M · Other health care · Apr 1, 2025
- Tectonic Therapeutic, Inc.$185M · Biotech · Feb 14, 2025
- Organogenesis Holdings Inc.$130M · Biotech · Nov 27, 2024
- Solstice Oncology, Inc.$121M · Biotech · Mar 9, 2026
- Triana Biomedicines, Inc.$120M · Pharma · Dec 4, 2025
State Attorney General Health-Care Cases
Antitrust cases Massachusetts joined, newest first; see every case- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)2019 · Pending
- Commonwealth v. Beth Israel Lahey Health, Inc. No. 2018-3703, Sussex Super. Ct., Mass Nov. 29, 2018)2018 · Assurance of discontinuance
- State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)2016 · Pending
- Connecticut et al. v. Teva Pharmaceuticals et al. Civ. Action No. (D.Conn. Dec. 15, 2016)2016 · Pending
- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
- Massachusetts v. Partners Healthcare System Inc. et al., no. 14-2033 (Mass. Super. Ct. June 24 2014)2014 · Transaction abandoned
- Florida et al. v. Abbott Laboratories et al., No. 1:08-cv-00155-SLR (D.Del. 2007)2007 · Settled
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
- State of Colorado et al v. Warner Chilcott, 1:05-cv-02182 (D.D.C.2005)2005 · Settled
Other States
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG